Guidelines for the management of oesophageal and gastric cancer

Gut

Volumn 60, Issue 11, 2011, Pages 1449-1472

  Allum, William H ^a   Blazeby, Jane M ^b   Griffin, S Michael ^c   Cunningham, David ^a   Jankowski, Janusz A ^d   Wong, Rachel ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESOMEPRAZOLE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXALIPLATIN; PACLITAXEL; PHOTOFRIN; PLATINUM COMPLEX; TRASTUZUMAB;

ANTIREFLUX OPERATION; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; BRACHYTHERAPY; BRONCHOSCOPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOPULMONARY EXERCISE TEST; CHEMORADIOTHERAPY; CHROMOENDOSCOPY; CLINICAL NURSE SPECIALIST; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST CONTROL; CRYOTHERAPY; DRUG COST; DYSPHAGIA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SUBMUCOSAL DISSECTION; ENDOSCOPIC THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS DILATATION; ESOPHAGUS INTUBATION; ESOPHAGUS PERFORATION; ESOPHAGUS RESECTION; EVIDENCE BASED MEDICINE; EXERCISE TEST; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL ENDOSCOPY; GASTROSCOPY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LAPAROSCOPY; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; MEDICAL DECISION MAKING; MONOTHERAPY; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PATIENT REFERRAL; PERIOPERATIVE PERIOD; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SALVAGE THERAPY; STENT; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER; STOMACH CARCINOMA; STOMACH ULCER; SYMPTOM; TRACHEOESOPHAGEAL FISTULA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; BRONCHOSCOPY; CARCINOMA, SQUAMOUS CELL; CATHETER ABLATION; CHEMORADIOTHERAPY, ADJUVANT; CRYOTHERAPY; ELECTROCOAGULATION; ESOPHAGEAL NEOPLASMS; EXERCISE TEST; GASTRECTOMY; GREAT BRITAIN; HEMODYNAMICS; HOSPITAL MORTALITY; HUMANS; LYMPH NODE EXCISION; NEOPLASM STAGING; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PALLIATIVE CARE; PHOTOCHEMOTHERAPY; REFERRAL AND CONSULTATION; STATE MEDICINE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 80053573654     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.228254     Document Type: Review

References (289)

1. National Oesophago-Gastric Cancer audit. First Annual Report - 2008. London: The NHS Information Centre, 2008.
2. National Oesophago-Gastric Cancer audit. Second Annual Report - 2009. London: The NHS Information Centre, 2009.
3. National Oesophago-Gastric Cancer Audit. Third Annual Report. 1-69. London: The NHS Information Centre, 2010.
4. Department of Health. The NHS Cancer Plan - a Plan for Investment, a Plan for Reform. London: Department of Health, 2000.
5. Allum WH, Griffin SM, Watson A, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2002;50(Suppl 5):v1-23.
6. Eccles M, Rousseau N, Freemantle N. Updating evidence-based clinical guidelines. J Health Serv Res Policy 2002;7:98-103. (Pubitemid 34984015)
7. Cheng KK, Sharp L, McKinney PA, et al. A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 2000;83:127-32. (Pubitemid 30352729)
8. Lindblad M, Rodriguez LA, Lagergren J. Body mass, tobacco and alcohol and risk of oesophageal, gastric cardia and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 2005;16:285-94. (Pubitemid 40897847)
9. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: a cohort study. BMJ 2007;335:1134.
10. Ryan AM, Healy LA, Power DG, et al. Barrett's oesophagus: prevalence of central adiposity, metabolic syndrome, and a pro-inflammatory state. Ann Surg 2008;247:909-15. (Pubitemid 351770409)
11. Hansen S, Vollset SE, Derakhshan MH, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007;56:918-25. (Pubitemid 46999074)
12. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2006;55:1810-20.
13. Norwood MG, Bailey N, Nanji M, et al. Cytoplasmic beta-catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas. Histopathology 2010;57:101-11.
14. Jankowski J, Barr H. Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ 2006;332:1512. (Pubitemid 44365302)
15. Robertson EV, Jankowski JA. Genetics of gastroesophageal cancer: paradigms, paradoxes, and prognostic utility. Am J Gastroenterol 2008;103:443-9. (Pubitemid 351248711)
16. HMSO (Her Majesty's Stationery Office). NHS Executive Referral Guidelines for Suspected Cancer; 1-4. 14 April 2000, London: Department of Health, 2011.
17. Hallissey MT, Allum WH, Jewkes AJ, et al. Early detection of gastric cancer. BMJ 1990;301:513-15. (Pubitemid 20320919)
18. Bowrey DJ, Griffin SM, Wayman J, et al. Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked. Surg Endosc 2006;20:1725-8. (Pubitemid 44715537)
19. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB, et al. Predicting endoscopic diagnosis in the dyspeptic patient. The value of predictive score models. Scand J Gastroenterol 1997;32:118-25. (Pubitemid 27075116)
20. Joint Advisory Group on Gastrointestinal Endoscopy. Guidelines for the Training, Appraisal and Assessment of Trainees in Gastrointestinal Endoscopy and for the Assessment of Units for Registration and Re-Registration. 2004:1-48. http://www.thejag.org.uk.
21. Bramble MG, Suvakovic Z, Hungin AP. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000;46:464-7. (Pubitemid 30305808)
22. Yalamarthi S, Witherspoon P, McCole D, et al. Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy 2004;36:874-9. (Pubitemid 39307137)
23. Fitzgerald RC, Saeed IT, Khoo D, et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001;46:1892-8. (Pubitemid 32844155)
24. Lal N, Bhasin DK, Malik AK, et al. Optimal number of biopsy specimens in the diagnosis of carcinoma of the oesophagus. Gut 1992;33:724-6.
25. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40-50. (Pubitemid 23234018)
26. Wayman J, Hayes N, Griffin SM. The response of early gastric cancer to proton-pump inhibitors. N Engl J Med 1998;338:1924-5. (Pubitemid 28287872)
27. Di Franco F, Lamb PJ, Karat D, et al. Iatrogenic perforation of localized oesophageal cancer. Br J Surg 2008;95:837-9.
28. Inoue H, Rey JF, Lightdale C. Lugol chromoendoscopy for esophageal squamous cell cancer. Endoscopy 2001;33:75-9. (Pubitemid 32586362)
29. Sakai Y, Eto R, Kasanuki J, et al. Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia: a prospective comparative study. Gastrointest Endosc 2008;68:635-41.
30. Pohl J, Pech O, May A, et al. Incidence of macroscopically occult neoplasias in Barrett's esophagus: are random biopsies dispensable in the era of advanced endoscopic imaging?. Am J Gastroenterol 2010;105:2350-6.
31. Curvers WL, Singh R, Song LM, et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut 2008;57:167-72. (Pubitemid 351158041)
32. Jankowski JA, Odze RD. Biomarkers in gastroenterology: between hope and hype comes histopathology. Am J Gastroenterol 2009;104:1093-6.
33. Kadri SR, Lao-Sirieix P, O'Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010;341:c4372.
34. Stroppa I, Grasso E, Paoluzi OA, et al. Unsedated transnasal versus transoral sedated upper gastrointestinal endoscopy: a one-series prospective study on safety and patient acceptability. Dig Liver Dis 2008;40:767-75.
35. Fitzgerald R, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future management. J Med Genet 2010;47:436-44.
36. Donaldson L. 150 years of the Annual Report of the Chief Medical Officer: on the state of public health 2008. Annual Report of the Chief Medical Officer; 1-73. 16 March 2009, Department of Health, 2011. http://www.dh.gov.uk.
37. Wani S, Mathur SC, Curvers WL, et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia. Clin Gastroenterol Hepatol 2010;8:783-8.
38. Curvers WL, Bansal A, Sharma P, et al. Endoscopic work-up of early Barrett's neoplasia. Endoscopy 2008;40:1000-7.
39. Mino-Kenudson M, Hull MJ, Brown I, et al. EMR for Barrett's esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc 2007;66:660-6. (Pubitemid 47495911)
40. Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endosc 2008;67:604-9.
41. Bhandari S, Shim CS, Kim JH, et al. Usefulness of three-dimensional, multidetector row CT (virtual gastroscopy and multiplanar reconstruction) in the evaluation of gastric cancer: a comparison with conventional endoscopy, EUS, and histopathology. Gastrointest Endosc 2004;59:619-26. (Pubitemid 38609689)
42. Fukuya T, Honda H, Kaneko K, et al. Efficacy of helical CT in T-staging of gastric cancer. J Comput Assist Tomogr 1997;21:73-81. (Pubitemid 27061159)
43. Hur J, Park MS, Lee JH, et al. Diagnostic accuracy of multidetector row computed tomography in T- and N staging of gastric cancer with histopathologic correlation. J Comput Assist Tomogr 2006;30:372-7. (Pubitemid 43922252)
44. Kim HJ, Kim AY, Oh ST, et al. Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning. Radiology 2005;236:879-85. (Pubitemid 41170851)
45. Penman I, Norton S, Harris K. Staging of Oesophago-Gastric Carcinoma by Endoscopic Ultrasonography: Guidance and Minimum Standards; 1-19. 2011, EUS Users Group and the British Society of Gastroenterology (BSG), 2011.
46. Catalano MF, Sivak MV Jr, Bedford RA, et al. Observer variation and reproducibility of endoscopic ultrasonography. Gastrointest Endosc 1995;41:115-20.
47. Pfau PR, Ginsberg GG, Lew RJ, et al. Esophageal dilation for endosonographic evaluation of malignant esophageal strictures is safe and effective. Am J Gastroenterol 2000;95:2813-15.
48. Mallery S, van Dam J. Increased rate of complete EUS staging of patients with esophageal cancer using the nonoptical, wire-guided echoendoscope. Gastrointest Endosc 1999;50:53-7. (Pubitemid 29323289)
49. Bhutani MS, Hawes RH, Hoffman BJ. A comparison of the accuracy of echo features during endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration for diagnosis of malignant lymph node invasion. Gastrointest Endosc 1997;45:474-9. (Pubitemid 27424397)
50. Catalano MF, Sivak MV Jr, Rice T, et al. Endosonographic features predictive of lymph node metastasis. Gastrointest Endosc 1994;40:442-6. (Pubitemid 24235572)
51. Vazquez-Sequeiros E, Norton ID, Clain JE, et al. Impact of EUS-guided fine-needle aspiration on lymph node staging in patients with esophageal carcinoma. Gastrointest Endosc 2001;53:751-7. (Pubitemid 33717249)
52. Wallace MB, Kennedy T, Durkalski V, et al. Randomized controlled trial of EUS-guided fine needle aspiration techniques for the detection of malignant lymphadenopathy. Gastrointest Endosc 2001;54:441-7. (Pubitemid 33661147)
53. Eloubeidi MA, Seewald S, Tamhane A, et al. EUS-guided FNA of the left adrenal gland in patients with thoracic or GI malignancies. Gastrointest Endosc 2004;59:627-33. (Pubitemid 38609690)
54. Dassen AE, Lips DJ, Hoekstra CJ, et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 2009;35:449-55.
55. Chowdhury FU, Bradley KM, Gleeson FV. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma. Clin Radiol 2008;63:1297-309.
56. Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 2007;133:738-45.
57. De Graaf GW, Ayantunde AA, Parsons SL, et al. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007;33:988-92. (Pubitemid 47408736)
58. Nath J, Moorthy K, Taniere P, et al. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg 2008;95:721-6.
59. Sohn KM, Lee JM, Lee SY, et al. Comparing MR imaging and CT in the staging of gastric carcinoma. AJR Am J Roentgenol 2000;174:1551-7. (Pubitemid 30346712)
60. Wu LF, Wang BZ, Feng JL, et al. Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography, spiral CT and MRI. World J Gastroenterol 2003;9:219-24.
61. Yamada I, Izumi Y, Kawano T, et al. Superficial esophageal carcinoma: an in vitro study of high-resolution MR imaging at 1.5T. J Magn Reson Imaging 2001;13:225-31. (Pubitemid 32066659)
62. Riddell AM, Allum WH, Thompson JN, et al. The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlation. Eur Radiol 2007;17:391-9. (Pubitemid 46140310)
63. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT - a multicenter trial. J Comput Assist Tomogr 2006;30:345-54. (Pubitemid 43922248)
64. Semelka RC, Martin DR, Balci C, et al. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001;13:397-401. (Pubitemid 32173407)
65. Omloo JM, van Heijl M, Bergman JJ, et al. Value of bronchoscopy after EUS in the preoperative assessment of patients with esophageal cancer at or above the carina. J Gastrointest Surg 2008;12:1874-9.
66. Mapstone NP. Standards and Datasets for Reporting Cancers - Dataset for the Histopathological Reporting of Oesophageal Carcinoma. 2nd edn. 1-15. 2007, London: The Royal College of Pathologists, 2011.
67. Watson A, Heading RC, Shepherd NA, et al. Guidelines for the Diagnosis and Management of Barrett's Columnar-Lined Oesophagus. 2005:1-40. http://www.bsg.org.uk.
68. King PM, Blazeby JM, Gupta J, et al. Upper gastrointestinal cancer pathology reporting: a regional audit to compare standards with minimum datasets. J Clin Pathol 2004;57:702-5. (Pubitemid 38901483)
69. National Cancer Intelligence Network. National Cancer Intelligence Network (NCIN)dncin.org.uk. National Cancer Intelligence Network, 2011. http://www.ncin.org.uk.
70. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-68.
71. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002;51:130-1. (Pubitemid 34717758)
72. International Agency for Research on Cancer (IARC). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Hamilton SR and Aaltonen LA. 1-4. 2000, Lyon, IARC Press, 2011.
73. Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg 2006;95:260-9. (Pubitemid 46089261)
74. Sobin LH, Wittekind C. Oesophagus (ICD-O C15). In: Sobin LH, Wittkind C, eds. TNM Classification of Malignant Tumours. New York: A John Wiley & Sons, Inc, 2002:60-9.
75. UICC. TNM Classification of Malignant Tumours. 5th edn. Berlin: Springer-Verlag, 1997.
76. UICC, International Union Against Cancer. TNM Classification of Malignant Tumours. 6th edn. New York: Wiley-Blackwell Press, 2002.
77. Fletcher GF, Balady G, Froelicher VF, et al. Exercise standards. A statement for healthcare professionals from the American Heart Association. Writing Group. Circulation 1995;91:580-615.
78. Girish M, Trayner E Jr, Dammann O, et al. Symptom limited stair climbing as a predictor of postoperative cardiopulmonary complications after high risk surgery. Chest 2001;120:1147-51. (Pubitemid 32960085)
79. Older P, Smith R, Hall A, et al. Preoperative cardiopulmonary risk assessment by cardiopulmonary exercise testing. Crit Care Resusc 2000;2:198-208.
80. Nagamatsu Y, Shima I, Yamana H, et al. Preoperative evaluation of cardiopulmonary reserve with the use of expired gas analysis during exercise testing in patients with squamous cell carcinoma of the thoracic esophagus. J Thorac Cardiovasc Surg 2001;121:1064-8.
81. Forshaw M, Strauss D, Davies A, et al. Is cardiopulmonary exercise testing a useful test before esophagectomy? Ann Thorac Med 2008;85:294-9. (Pubitemid 350265783)
82. Singh SJ, Morgan MD, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992;47:1019-24. (Pubitemid 23011018)
83. Murray P, Whiting P, Hutchinson SP, et al. Preoperative shuttle walking testing and outcome after oesophagogastrectomy. Br J Anaesth 2007;99:809-11. (Pubitemid 351773382)
84. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007;116:1971-96.
85. Deans DA, Wigmore SJ, De Beaux AC, et al. Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. Br J Surg 2007;94:1501-8. (Pubitemid 350275629)
86. National Collaborating Centre for Acute Care. Nutrition Support for Adults Oral Nutrition Support, Enteral Tube Feeding and Parenteral Nutrition - Methods, Evidence and Guidance; 1-176. 2006, London: National Collaborating Centre for Acute Care at The Royal College of Surgeons of England, 2011.
87. Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 1996;27:910-48.
88. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. J Am Coll Cardiol 2006;47:2343-55.
89. Biccard BM, Sear JW, Foex P. Meta-analysis of the effect of heart rate achieved by perioperative beta-adrenergic blockade on cardiovascular outcomes. Br J Anaesth 2008;100:23-8. (Pubitemid 351773420)
90. Hindler K, Shaw AD, Samuels J, et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006;105:1260-72. (Pubitemid 44808591)
91. Kapoor AS, Kanji H, Buckingham J, et al. Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies. BMJ 2006;333:1149.
92. Shoemaker WC, Appel PL, Kram HB. Role of oxygen debt in the development of organ failure sepsis, and death in high-risk surgical patients. Chest 1992;102:208-15.
93. Wilson J, Woods I, Fawcett J, et al. Reducing the risk of major elective surgery: randomised controlled trial of preoperative optimisation of oxygen delivery. BMJ 1999;318:1099-103. (Pubitemid 29192147)
94. Neal JM, Wilcox RT, Allen HW, et al. Near-total esophagectomy: the influence of standardized multimodal management and intraoperative fluid restriction. Reg Anesth Pain Med 2003;28:328-34. (Pubitemid 36936258)
95. Weimann A, Braga M, Harsanyi L, et al. ESPEN Guidelines on Enteral Nutrition: Surgery including organ transplantation. Clin Nutr 2006;25:224-44. (Pubitemid 43832525)
96. Bozzetti F, Braga M, Gianotti L, et al. Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet 2001;358:1487-92. (Pubitemid 33055699)
97. Farreras N, Artigas V, Cardona D, et al. Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. Clin Nutr 2005;24:55-65.
98. Gianotti L, Braga M, Nespoli L, et al. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology 2002;122:1763-70. (Pubitemid 34651419)
99. Braga M, Gianotti L, Nespoli L, et al. Nutritional approach in malnourished surgical patients: a prospective randomized study. Arch Surg 2002;137:174-80. (Pubitemid 34142134)
100. Braga M, Gianotti L, Vignali A, et al. Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer. Surgery 2002;132:805-14. (Pubitemid 36307818)
101. National Clinical Guideline Centre - Acute and Chronic Conditions (formerly the National Collaborating Centre for Acute Care). Reducing the Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Hospital CG92. 2010:1-509. http://www.nice.org.uk.
102. NICE (National Institute for Health and Clinical Excellence). Barrett's Oesophagus - Ablative Therapy for the Treatment of Barrett's Oesophagus CG106. 1. 11 August 2010, 2011. http://www.nice.org.uk.
103. NICE (National Institute for Health and Clinical Excellence). Endoscopic Submucosal Dissection (ESD) of Oesophageal Dysplasia and Neoplasia: Guidance IPG355. 1-2. 2010, 2011. http://www.nice.org.uk.
104. Li YM, Li L, Yu CH, et al. A systematic review and meta-analysis of the treatment for Barrett's esophagus. Dig Dis Sci 2008;53:2837-46.
105. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:1200-6.
106. Sugano K. Gastric cancer: pathogenesis, screening, and treatment. Gastrointest Endosc Clin N Am 2008;18:513-22, ix.
107. Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005;242:566-73.
108. Kodama M, Kakegawa T. Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery 1998;123:432-9. (Pubitemid 28201225)
109. Barr H. Surgical efficiency or eradication sufficiency. Am J Gastroenterol 2008;103:1346-8. (Pubitemid 351813938)
110. Das A, Singh V, Fleischer DE, et al. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol 2008;103:1340-5. (Pubitemid 351813937)
111. Kantsevoy SV, Adler DG, Conway JD, et al. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc 2008;68:11-18. (Pubitemid 351842803)
112. Ciocirlan M, Lapalus MG, Hervieu V, et al. Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus. Endoscopy 2007;39:24-9. (Pubitemid 46430264)
113. Inoue H, Fukami N, Yoshida T, et al. Endoscopic mucosal resection for esophageal and gastric cancers. J Gastroenterol Hepatol 2002;17:382-8. (Pubitemid 34534074)
114. Takeshita K, Tani M, Inoue H, et al. Endoscopic treatment of early oesophageal or gastric cancer. Gut 1997;40:123-7. (Pubitemid 27079763)
115. Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008;40:359-69. (Pubitemid 351696372)
116. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-88.
117. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007;132:1226-33. (Pubitemid 46627583)
118. Sibille A, Lambert R, Souquet JC, et al. Long-term survival after photodynamic therapy for oesophageal cancer. Gastroenterology 1995;108:337-44.
119. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999;49:1-7. (Pubitemid 29076815)
120. Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol 2006;101:1449-57. (Pubitemid 43980615)
121. Barr H, Kendall C, Stone N. Photodynamic therapy for esophageal cancer: a useful and realistic option. Technol Cancer Res Treat 2003;2:65-76.
122. Moghissi K, Dixon K. Photodynamic therapy (PDT) in esophageal cancer: a surgical view of its indications based on 14 years experience. Technol Cancer Res Treat 2003;2:319-26. (Pubitemid 37022348)
123. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58:183-8. (Pubitemid 38220265)
124. Corti L, Skarlatos J, Boso C, et al. Outcome of patients receiving photodynamic therapy for early esophageal cancer. Int J Radiat Oncol Biol Phys 2000;47:419-24. (Pubitemid 30236384)
125. Radu A, Wagnieres G, van den Bergh H, et al. Photodynamic therapy of early squamous cell cancers of the esophagus. Gastrointest Endosc Clin N Am 2000;10:439-60. (Pubitemid 30429685)
126. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007;66:460-8. (Pubitemid 47304412)
127. Shaheen NJ, Inadomi JM, Overholt BF, et al. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut 2004;53:1736-44. (Pubitemid 39556888)
128. Vij R, Triadafilopoulos G, Owens DK, et al. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 2004;60:739-56. (Pubitemid 39550931)
129. Spechler SJ. Thermal ablation of Barrett's esophagus: a heated debate. Am J Gastroenterol 2006;101:1770-2. (Pubitemid 44166584)
130. Basu KK, Pick B, Bale R, et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut 2002;51:776-80. (Pubitemid 35408594)
131. Kahaleh M, van Laethem JL, Nagy N, et al. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002;34:950-5. (Pubitemid 35446323)
132. Manner H, May A, Miehlke S, et al. Ablation of nonneoplastic Barrett's mucosa using argon plasma coagulation with concomitant esomeprazole therapy (APBANEX): a prospective multicenter evaluation. Am J Gastroenterol 2006;101:1762-9. (Pubitemid 44166583)
133. van Laethem JL, Cremer M, Peny MO, et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998;43:747-51. (Pubitemid 28539651)
134. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-14. (Pubitemid 29141051)
135. Pereira-Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol 2000;95:1661-8. (Pubitemid 30484999)
136. Hage M, Siersema PD, van Dekken H, et al. 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut 2004;53:785-90. (Pubitemid 38662126)
137. Kelty CJ, Ackroyd R, Brown NJ, et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004;20:1289-96. (Pubitemid 40040075)
138. Ragunath K, Krasner N, Raman VS, et al. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol 2005;40:750-8. (Pubitemid 40978849)
139. Dulai GS, Jensen DM, Cortina G, et al. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc 2005;61:232-40. (Pubitemid 40261071)
140. Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008;40:370-9. (Pubitemid 351696373)
141. Hubbard N, Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus in patients with fundoplications. Surg Endosc 2007;21:625-8. (Pubitemid 46439386)
142. Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg 1992;79:241-4.
143. Yamao T, Shirao K, Ono H, et al. Risk factors for lymph node metastasis from intramucosal gastric carcinoma. Cancer 1996;77:602-6. (Pubitemid 26055382)
144. Rugge M, Cassaro M, Di Mario F, et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003;52:1111-16. (Pubitemid 36877421)
145. Tsukuma H, Oshima A, Narahara H, et al. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut 2000;47:618-21.
146. Uedo N, Iishi H, Tatsuta M, et al. Longterm outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer 2006;9:88-92. (Pubitemid 43885766)
147. Bachmann MO, Alderson D, Edwards D, et al. Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. Br J Surg 2002;89:914-22. (Pubitemid 34779578)
148. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-37. (Pubitemid 34984604)
149. Department of Health. Guidance on Commissioning Cancer Services: Improving Outcomes in Upper Gastro-Intestinal Cancers. London: Department of Health, 2001:1-96.
150. Sutton DN, Wayman J, Griffin SM. Learning curve for oesophageal cancer surgery. Br J Surg 1998;85:1399-402. (Pubitemid 28468346)
151. Parikh D, Johnson M, Chagla L, et al. D2 gastrectomy: lessons from a prospective audit of the learning curve. Br J Surg 1996;83:1595-9. (Pubitemid 26365088)
152. AUGIS, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, and Clinical Services Committee. AUGIS Recommendations on Minimum Volumes 2010. AUGIS Guidance on Minimum Surgeon Volumes 2010. 2011. http://www.augis.org.
153. Hulscher JB, van Sandick JW, De Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-9. (Pubitemid 35340784)
154. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246:992-1000. (Pubitemid 350179188)
155. De Boer AG, van Lanschot JJ, van Sandick JW, et al. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J Clin Oncol 2004;22:4202-8. (Pubitemid 41185191)
156. Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008;248:549-56.
157. Blazeby JM, Farndon JR, Donovan JL, et al. A prospective longitudinal study examining the quality of life of patients with esophageal cancer. Cancer 2000;88:1781-7. (Pubitemid 30212985)
158. Reynolds JV, McLaughlin R, Moore J, et al. Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J Surg 2006;93:1084-90. (Pubitemid 44343505)
159. Viklund P, Wengstrom Y, Rouvelas I, et al. Quality of life and persisting symptoms after oesophageal cancer surgery. Eur J Cancer 2006;42:1407-14. (Pubitemid 43903151)
160. Djarv T, Lagergren J, Blazeby JM, et al. Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg 2008;95:1121-6.
161. Lagergren P, Avery KN, Hughes R, et al. Health-related quality of life among patients cured by surgery for esophageal cancer. Cancer 2007;110:686-93. (Pubitemid 47106160)
162. Berrisford RG, Wajed SA, Sanders D, et al. Short-term outcomes following total minimally invasive oesophagectomy. Br J Surg 2008;95:602-10.
163. Luketich JD, velo-Rivera M, Buenaventura PO, et al. Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003;238:486-95.
164. Palanivelu C, Prakash A, Senthilkumar R, et al. Minimally invasive esophagectomy: thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position - experience of 130 patients. J Am Coll Surg 2006;203:7-16.
165. Singhal R, Pallan L, Taniere P, et al. Oncological acceptability of laparoscopic surgery for locally advanced oesophageal adenocarcinoma. Br J Surg 2008;95(Suppl 3):12.
166. Parameswaran R, Blazeby JM, Hughes R, et al. Health-related quality of life after minimally invasive oesophagectomy. Br J Surg 2010;97:525-31.
167. Hardwick RH; AUGIS, The Association of Upper Gastrointestinal Surgeons, The Association of Laparoscopic Surgeons of Great Britain & Ireland, and ALS. A Consensus View and Recommendations on the Development and Practice of Minimally Invasive Oesophagectomy. 1-8. 2009, AUGIS, 2011. http://www.augis.org.
168. Barbour AP, Rizk NP, Gonen M, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg 2007;246:1-8. (Pubitemid 47012198)
169. Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006;7:644-51. (Pubitemid 44123569)
170. Barbour AS, Lagergren P, Hughes R, et al. Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy. Br J Surg 2008;95:80-4. (Pubitemid 351184918)
171. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-30. (Pubitemid 29116815)
172. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer. Preliminary results of the MRC randomised controlled surgical trial. Lancet 1996;347:995-9. (Pubitemid 26112171)
173. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49.
174. Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998;123:573-8. (Pubitemid 28215371)
175. Roviello F, Marrelli D, Morgagni P, et al. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. Ann Surg Oncol 2002;9:894-900. (Pubitemid 35265641)
176. Yildirim E, Celen O, Berberoglu U. The Turkish experience with curative gastrectomies for gastric carcinoma: is D2 dissection worthwhile? J Am Coll Surg 2001;192:25-37. (Pubitemid 32064095)
177. Degiuli M, Sasako M, Ponti A, et al. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727-32. (Pubitemid 38725642)
178. Robertson CS, Chung SC, Woods SD, et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994;220:176-82. (Pubitemid 24309416)
179. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309-15.
180. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62.
181. Yonemura Y, Wu CC, Fukushima N, et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008;13:132-7. (Pubitemid 351668170)
182. Lamb P, Sivashanmugam T, White M, et al. Gastric cancer surgery - a balance of risk and radicality. Ann R Coll Surg Engl 2008;90:235-42. (Pubitemid 351593724)
183. Sano T. Tailoring treatments for curable gastric cancer. Br J Surg 2007;94:263-4. (Pubitemid 46423841)
184. Huscher CG, Mingoli A, Sgarzini G, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg 2005;241:232-7.
185. Tanimura S, Higashino M, Fukunaga Y, et al. Laparoscopic gastrectomy with regional lymph node dissection for upper gastric cancer. Br J Surg 2007;94:204-7. (Pubitemid 46340401)
186. Memon MA, Khan S, Yunus RM, et al. Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surg Endosc 2008;22:1781-9.
187. Wu CW, Chiou JM, Ko FS, et al. Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial. Br J Cancer 2008;98:54-9.
188. Kim YW, Baik YH, Yun YH, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 2008;248:721-7.
189. Avery K, Hughes R, McNair A, et al. Health-related quality of life and survival in the 2 years after surgery for gastric cancer. Eur J Surg Oncol 2010;36:148-54.
190. Svedlund J, Sullivan M, Liedman B, et al. Long term consequences of gastrectomy for patient's quality of life: the impact of reconstructive techniques. Am J Gastroenterol 1999;94:438-45. (Pubitemid 29084666)
191. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005;(4):CD001799.
192. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34. (Pubitemid 46291702)
193. Gaast AV, van Hagen P, Hulshof MASCO. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. J Clin Oncol 2010;25(15 Suppl):Suppl Abs. 4004.
194. Mariette C, Seitz J, Maillard E, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901. J Clin Oncol 2010;28(15 Suppl):Suppl Abs. 4005.
195. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6.
196. van ME, van der Gaast A, Looman CW, et al. Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma. Int J Radiat Oncol Biol Phys 2008;71:160-6.
197. Safieddine N, Xu W, Quadri SM, et al. Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradiotherapy followed by surgical intervention. J Thorac Cardiovasc Surg 2009;137:36-42.
198. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006;(1):CD002092.
199. Chiu PW, Chan AC, Leung SF, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005;9:794-802. (Pubitemid 40883974)
200. Carstens H, Albertsson M, Friesland S, et al. A randomized trial of chemoradiotherapy versus surgery alone in patients with resectable esophageal cancer. J Clin Oncol 2007;25:Suppl Abs. 4530.
201. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-17. (Pubitemid 46218723)
202. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-8. (Pubitemid 46640561)
203. Bonnetain F, Bouche O, Michel P, et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol 2006;17:827-34.
204. Avery KN, Metcalfe C, Barham CP, et al. Quality of life during potentially curative treatment for locally advanced oesophageal cancer. Br J Surg 2007;94:1369-76. (Pubitemid 350144385)
205. Anderson SE, Minsky BD, Bains M, et al. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer 2007;96:1823-7. (Pubitemid 46912031)
206. Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ. Salvage oesophagectomy after local failure of definitive chemoradiotherapy. Br J Surg 2007;94:1059-66. (Pubitemid 350082848)
207. Wenger U, Luo J, Lundell L, et al. A nationwide study of the use of self-expanding stents in patients with esophageal cancer in Sweden. Endoscopy 2005;37:329-34. (Pubitemid 40561655)
208. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
209. Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062-7.
210. Kelsen D, Ginsberg RJ, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localised oesophageal cancer. N Engl J Med 1998;339:1979-84. (Pubitemid 29024130)
211. Blazeby JM, Sanford E, Falk SJ, et al. Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer 2005;103:1791-9. (Pubitemid 40563250)
212. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
213. Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1751-21.
214. Gianni L, Panzini I, Tassinari D, et al. Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann Oncol 2001;12:1178-80.
215. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002;168:597-608. (Pubitemid 36355892)
216. Liu TS, Wang Y, Chen SY, et al. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008;34:1208-16.
217. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20. (Pubitemid 350044801)
218. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
219. Macdonald JS, Benedetti J, Smalley S, et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 2009;27(15 Suppl), Suppl Abs. 4515.
220. Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer 2004;91:447-52. (Pubitemid 39093562)
221. Ravasco P, Monteiro-Grillo I, Vidal PM, et al. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005;23:1431-8.
222. Siddiqui AA, Loren D, Dudnick R, et al. Expandable polyester silicon-covered stent for malignant esophageal strictures before neoadjuvant chemoradiation: a pilot study. Dig Dis Sci 2007;52:823-9.
223. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
224. Glimelius B, Ekstrom K, Hoffman K, et al. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8. (Pubitemid 27112884)
225. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. (Pubitemid 23182046)
226. Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
227. NICE (National Institute for Health and Clinical Excellence). Capecitabine for the Treatment of Advanced Gastric Cancer TA 191. 2010:1-2, 2 March 2011. http://www.nice.org.uk.
228. van CE, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7. (Pubitemid 46631401)
229. Wagner AD, Grothe W, Haerting J, et al. Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis. J Clin Oncol 2007;25(18 Suppl): Suppl Abs. 4555.
230. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999;80:269-72. (Pubitemid 29210117)
231. Webb A, Cunningham D, Scarffe JH, et al. Randomised trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methrotrexate in advanced oesophagogastric cancer. J Clin Oncol 1997;15:261-7. (Pubitemid 27020582)
232. Kang Y, Kang WK, Shin DB, et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J Clin Oncol 2006;24(18 Suppl):LBA4018.
233. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007;25:3217-23. (Pubitemid 47325604)
234. van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009;27(18 Suppl):LBA4509.
235. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev 2007;33:315-24. (Pubitemid 46766416)
236. Caspers RJL, Welvaart K, Verkes RJ, et al. The effect of radiotherapy on dysphagia and survival in patients with oesophageal cancer. Radiother Oncol 1988;12:15-23.
237. Cwikiel M, Cwikiel W, Albertsson M. Palliation of dysphagia in patients with malignant oesophageal strictures. Comparison of results of radiotherapy, chemotherapy and oesophageal stent treatment. Acta Oncol 1996;35:75-9.
238. Wara WM, Mauch PM, Thomas AN, et al. Palliation for carcinoma of the oesophagus. Radiology 1976;121:717-20.
239. Shenfine J, McNamee P, Steen N, et al. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technol Assess 2005;9:1-136.
240. Sabharwal T, Hamady MS, Chui S, et al. A randomised prospective comparison of the flamingo wallstent and ultraflex stent for palliation of dysphagia associated with lower third oesophageal carcinoma. Gut 2003;52:922-6. (Pubitemid 36765279)
241. Vakil N, Morris AI, Marcon N, et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am J Gastroenterol 2001;96:1791-6.
242. Homs MY, Wahab PJ, Kuipers EJ, et al. Esophageal stents with antireflux valve for tumors of the distal esophagus and gastric cardia: a randomized trial. Gastrointest Endosc 2004;60:695-702. (Pubitemid 39550925)
243. Conio M, Repici A, Battaglia G, et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. Am J Gastroenterol 2007;102:2667-77. (Pubitemid 350179354)
244. Verschuur EM, Repici A, Kuipers EJ, et al. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol 2008;103:304-12. (Pubitemid 351248705)
245. O'Donnell CA, Fullarton GM, Watt E, et al. Randomized clinical trial comparing self-expanding metallic stents with plastic endoprostheses in the palliation of oesophageal cancer. Br J Surg 2002;89:985-92. (Pubitemid 34994689)
246. Homann N, Noftz MR, Klingenberg-Noftz RD, et al. Delayed complications after placement of self-expanding stents in malignant esophageal obstruction: treatment strategies and survival rate. Dig Dis Sci 2008;53:334-40. (Pubitemid 351170005)
247. Kim JH, Song HY, Shin JH, et al. Membrane degradation of covered stents in the upper gastrointestinal tract: frequency and clinical significance. J Vasc Interv Radiol 2008;19:220-4.
248. Li XA, Chibani O, Greenwald B, et al. Radiotherapy dose perturbation of metallic esophageal stents. Int J Radiat Oncol Biol Phys 2002;54:1276-85. (Pubitemid 35292642)
249. Iraha Y, Murayama S, Toita T, et al. Self-expandable metallic stent placement for patients with inoperable esophageal carcinoma: investigation of the influence of prior radiotherapy and chemotherapy. Radiat Med 2006;24:247-52. (Pubitemid 351194325)
250. Kaneko K, Ito H, Konishi K, et al. Implantation of self-expanding metallic stent for patients with malignant stricture after failure of definitive chemoradiotherapy for T3 or T4 esophageal squamous cell carcinomas. Hepatogastroenterology 2002;49:699-705. (Pubitemid 34615331)
251. Lecleire S, Di Fiore F, Ben-Soussan E, et al. Prior chemoradiotherapy is associated with a higher life-threatening complication rate after palliative insertion of metal stents in patients with oesophageal cancer. Aliment Pharmacol Ther 2006;23:1693-702. (Pubitemid 43846412)
252. Homs MY, Hansen BE, van BM, et al. Prior radiation and/or chemotherapy has no effect on the outcome of metal stent placement for oesophagogastric carcinoma. Eur J Gastroenterol Hepatol 2004;16:163-70. (Pubitemid 39049652)
253. Sumiyoshi T, Gotoda T, Muro K, et al. Morbidity and mortality after self-expandable metallic stent placement in patients with progressive or recurrent esophageal cancer after chemoradiotherapy. Gastrointest Endosc 2003;57:882-5. (Pubitemid 47241102)
254. Yakami M, Mitsumori M, Sai H, et al. Development of severe complications caused by stent placement followed by definitive radiation therapy for T4 esophageal cancer. Int J Clin Oncol 2003;8:395-8. (Pubitemid 38036097)
255. Kim JH, Song HY, Shin JH, et al. Palliative treatment of unresectable esophagogastric junction tumors: balloon dilation combined with chemotherapy and/or radiation therapy and metallic stent placement. J Vasc Interv Radiol 2008;19:912-17.
256. Homs MY, Essink-Bot ML, Borsboom GJ, et al. Quality of life after palliative treatment for oesophageal carcinoma - a prospective comparison between stent placement and single dose brachytherapy. Eur J Cancer 2004;40:1862-71. (Pubitemid 39036761)
257. Steyerberg EW, Homs MY, Stokvis A, et al. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc 2005;62:333-40. (Pubitemid 41187931)
258. Polinder S, Homs MY, Siersema PD, et al. Cost study of metal stent placement vs single-dose brachytherapy in the palliative treatment of oesophageal cancer. Br J Cancer 2004;90:2067-72. (Pubitemid 38869707)
259. Bergquist H, Wenger U, Johnsson E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus 2005;18:131-9. (Pubitemid 41801105)
260. Wenger U, Johnsson E, Bergquist H, et al. Health economic evaluation of stent or endoluminal brachytherapy as a palliative strategy in patients with incurable cancer of the oesophagus or gastro-oesophageal junction: results of a randomized clinical trial. Eur J Gastroenterol Hepatol 2005;17:1369-77. (Pubitemid 41830460)
261. Motilall SR, Modiba MC, Tsatsi LD, et al. Trial of self-expandable metallic stents in the palliation of tracheo-oesophageal fistula in carcinoma of the oesophagus. S Afr J Surg 2007;45:24-7.
262. White RE, Mungatana C, Topazian M. Expandable stents for iatrogenic perforation of esophageal malignancies. J Gastrointest Surg 2003;7:715-19.
263. Murthy S, Gonzalez-Stawinski GV, Rozas MS, et al. Palliation of malignant aerodigestive fistulae with self-expanding metallic stents. Dis Esophagus 2007;20:386-9. (Pubitemid 47323677)
264. Sihvo EI, Pentikainen T, Luostarinen ME, et al. Inoperable adenocarcinoma of the oesophagogastric junction: a comparative clinical study of laser coagulation versus self-expanding metallic stents with special reference to cost analysis. Eur J Surg Oncol 2002;28:711-15. (Pubitemid 36240569)
265. Xinopoulos D, Dimitroulopoulos D, Moschandrea I, et al. Natural course of inoperable esophageal cancer treated with metallic expandable stents: quality of life and cost-effectiveness analysis. J Gastroenterol Hepatol 2004;19:1397-402. (Pubitemid 40052859)
266. Konigsrainer A, Riedmann B, De VA, et al. Expandable metal stents versus laser combined with radiotherapy for palliation of unresectable esophageal cancer: a prospective randomized trial. Hepatogastroenterology 2000;47:724-7. (Pubitemid 30417282)
267. Dallal HJ, Smith GD, Grieve DC, et al. A randomized trial of thermal ablative therapy versus expandable metal stents in the palliative treatment of patients with esophageal carcinoma. Gastrointest Endosc 2001;54:549-57. (Pubitemid 33666025)
268. Guo JH, Teng GJ, Zhu GY, et al. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology 2008;247:574-81.
269. Litle VR, Luketich JD, Christie NA, et al. Photdynamic therapy as palliation for esophageal cancer: experience in 215 patients. Ann Thorac Surg 2003;76:1687-93. (Pubitemid 37378339)
270. Luketich JD, Christie NA, Buenaventura PO, et al. Endoscopic photodynamic therapy for obstructing esophageal cancer: 77 cases over a 2-year period. Surg Endosc 2000;14:653-7. (Pubitemid 30626218)
271. Lecleire S, Di Fiore F, Antonietti M, et al. Nonoperable patients with superficial esophageal cancer treated by photodynamic therapy after chemoradiotherapy have more severe complications than patients treated in primary intent. Am J Gastroenterol 2008;103:2215-19.
272. Eriksen JR. Palliation of non-resectable carcinoma of the cardia and oesophagus by argon beam coagulation. Dan Med Bull 2002;49:346-9. (Pubitemid 35434533)
273. Manner H, May A, Rabenstein T, et al. Prospective evaluation of a new high-power argon plasma coagulation system (hp-APC) in therapeutic gastrointestinal endoscopy. Scand J Gastroenterol 2007;42:397-405.
274. Akhtar K, Byrne JP, Bancewicz J, et al. Argon beam plasma coagulation in the management of cancers of the esophagus and stomach. Surg Endosc 2000;14:1127-30. (Pubitemid 32060360)
275. Carazzone A, Bonavina L, Segalin A, et al. Endoscopic palliation of oesophageal cancer: results of a prospective comparison of Nd:YAG laser and ethanol injection. Eur J Surg 1999;165:351-6. (Pubitemid 29377071)
276. Verschuur EM, Steyerberg EW, Tilanus HW, et al. Nurse-led follow-up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. Br J Cancer 2009;100:70-6.
277. Trevatt P, Leary A. A census of the advanced and specialist cancer nursing workforce in England, Northern Ireland and Wales. Eur J Oncol Nurs 2010;14:68-73.
278. National Cancer Action Team. National Cancer Peer Review Programme - Manual for Cancer Services 2008: Upper GI Measures; 1-86, 18 November 2008, Mayden Health, 2011. http://www.dh.gov.uk.
279. Hamric A, Spross J. The Clinical Nurse Specialist in Theory and Practice. 2nd edn. Philadelphia: Saunders, 1989.
280. Douglas HR, Halliday D, Normand C, et al. Economic evaluation of specialist cancer and palliative nursing: Macmillan evaluation study findings. Int J Palliat Nurs 2003;9:429-38.
281. Leary A, Crouch H, Lezard A, et al. Dimensions of clinical nurse specialist work in the UK. Nurs Stand 2008;23:40-4.
282. Cox CL, Ahluwalia S. Enhancing clinical effectiveness among clinical nurse specialists. Br J Nurs 2000;9:1064-70, 1071-3.
283. Sullivan A, Elliot S. Assessing the value of a cancer clinical nurse specialist. Cancer Nursing Practice 2007;6:25-8.
284. Catt S, Fallowfield L, Jenkins V, et al. The informational roles and psychological health of members of 10 oncology multidisciplinary teams in the UK. Br J Cancer 2005;93:1092-7. (Pubitemid 41670691)
285. National Cancer Action Team. Multidisciplinary Team Members' Views About MDT Working - Results from a Survey Commissioned by the National Cancer Action Team. Taylor C and Ramirez A. 1-58. 2009, 25 February 2011. http://www.ncin.org. uk.
286. Blazeby JM, Wilson L, Metcalfe C, et al. Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol 2006;17:457-60. (Pubitemid 43329583)
287. Blazeby JM, Conroy T, Bottomley A, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 2004;40:2260-8. (Pubitemid 39348876)
288. Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 2003;39:1384-94. (Pubitemid 36773781)
289. Lagergren P, Fayers P, Conroy T, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer 2007;43:2066-73. (Pubitemid 47380365)